Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayode Ogungbenro

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|March 22, 2006
Optimal design for multivariate response pharmacokinetic modelsIvelina Gueorguieva, Leon Aarons, Kayode Ogungbenro, et al.
Clinical Pharmacology and Therapeutics|June 2, 2022
Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney DiseaseHiroyuki Takita, Daniel Scotcher, Xiaoyan Chu, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2020
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluationAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 14, 2018
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin IShelby Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
European Journal of Clinical Pharmacology|June 8, 2019
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescentsKayode Ogungbenro, Jonathan B Wagner, Susan Abdel-Rahman, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2021
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexedAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Molecular Pharmaceutics|June 17, 2025
Challenges and Opportunities for Incorporating Physiological Information into Pharmacokinetic Models of Intranasal Drug Delivery to the Brain: A Review of the Current Status and Future TrajectoriesSaeed Rezaee, Zubida M Al-Majdoub, Aleksandra Galetin, et al.
Journal of Clinical Pharmacology|September 5, 2020
Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine BiasFarzaneh Salem, Trevor N Johnson, Arran B J Hodgkinson, et al.
Analytical Methods : Advancing Methods and Applications|March 21, 2023
Development of a sensitive biochemical assay for the detection of tofacitinib adherenceStephanie Church, Kimme L Hyrich, Kayode Ogungbenro, et al.
Clinical and Translational Science|November 11, 2025
Translatability of Animal Models for Alzheimer's Disease Using a Machine Learning Based WorkflowAlex Foster-Powell, Guy Meno-Tetang, Amin Rostami-Hodjegan, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Journal of Pharmacokinetics and Pharmacodynamics|March 22, 2006
Optimal design for multivariate response pharmacokinetic modelsIvelina Gueorguieva, Leon Aarons, Kayode Ogungbenro, et al.
Clinical Pharmacology and Therapeutics|June 2, 2022
Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney DiseaseHiroyuki Takita, Daniel Scotcher, Xiaoyan Chu, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2020
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluationAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 14, 2018
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin IShelby Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
European Journal of Clinical Pharmacology|June 8, 2019
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescentsKayode Ogungbenro, Jonathan B Wagner, Susan Abdel-Rahman, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2021
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexedAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Molecular Pharmaceutics|June 17, 2025
Challenges and Opportunities for Incorporating Physiological Information into Pharmacokinetic Models of Intranasal Drug Delivery to the Brain: A Review of the Current Status and Future TrajectoriesSaeed Rezaee, Zubida M Al-Majdoub, Aleksandra Galetin, et al.
Journal of Clinical Pharmacology|September 5, 2020
Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine BiasFarzaneh Salem, Trevor N Johnson, Arran B J Hodgkinson, et al.
Analytical Methods : Advancing Methods and Applications|March 21, 2023
Development of a sensitive biochemical assay for the detection of tofacitinib adherenceStephanie Church, Kimme L Hyrich, Kayode Ogungbenro, et al.
Clinical and Translational Science|November 11, 2025
Translatability of Animal Models for Alzheimer's Disease Using a Machine Learning Based WorkflowAlex Foster-Powell, Guy Meno-Tetang, Amin Rostami-Hodjegan, et al.
Pageof 10